Abstract: The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogs, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2.

Abstract: A pharmaceutical composition is provided having an effective amount of angiotensin-(1-9) and at least one pharmaceutical acceptable carrier, excipient, stabilizer, diluent, and/or adjuvant. Also provided is a method of using the pharmaceutical composition for inhibiting and/or reducing cardiovascular remodeling.

Abstract: The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogues, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2.

Abstract: The present invention relates to a pharmaceutical composition comprising an effective amount of angiotensin-(1-9) or derivatives thereof, and at least one pharmaceutical acceptable carrier, excipient, stabilizer, diluent, and/or adjuvant. Additionally, the present invention describes the use of the pharmaceutical composition and the angiotensin-(1-9) peptide or peptides derived thereof which are biological or chemical analogous for the manufacture of medicaments useful for preventing, reverting, inhibiting, and/or reducing cardiovascular, pulmonary, cerebral, or renal remodeling. Additionally, this invention also comprises a method for preventing, reverting, inhibiting, and/or reducing cardiovascular, pulmonary, cerebral, or renal remodeling comprising elevating blood and/or tissue concentration of angiotensin-(1-9) or derivatives thereof peptide via a pharmaceutical composition that contains a vector expressing ACE2, enzyme responsible for the endogenous production of angiotensin-(1-9).